What is Cirdan?
Established in 2010 and headquartered in the UK with offices in Canada and Australia, Cirdan specializes in enhancing and accelerating patient diagnosis through its advanced informatics software and imaging solutions. The company is recognized globally as a leading supplier of laboratory information systems. Cirdan's technology plays a crucial role in streamlining diagnostic workflows, improving accuracy, and ultimately benefiting patient care. The company's focus on innovation positions it as a key player in the digital health and medical imaging markets.
How much funding has Cirdan raised?
Cirdan has raised a total of $16M across 3 funding rounds:
Private Equity
$4.2M
Other Financing Round
$2.8M
Other Financing Round
$9M
Private Equity (2016): $4.2M with participation from Kainos Group plc
Other Financing Round (2023): $2.8M led by Kernel Capital and Clarendon Fund Managers
Other Financing Round (2024): $9M supported by Kernel Capital
Key Investors in Cirdan
Kernel Capital
Kernel Capital is a venture capital firm specializing in investing in growth and early-stage companies, providing both capital and strategic guidance to foster scaling and successful exits. They primarily support technology and innovation-driven businesses.
Clarendon Fund Managers
Clarendon Fund Managers manages Co-Fund NI, an initiative aimed at providing equity finance to Northern Ireland-based businesses with growth aspirations, investing alongside private investors to support scaling.
Kainos Group plc
Kainos Group plc is a digital services company offering technology solutions in cloud transformation, digital platforms, and data innovation, assisting organizations in modernizing systems and improving operational efficiency.
What's next for Cirdan?
The recent major strategic investment of $9M signals a new phase of expansion and development for Cirdan. This capital infusion is expected to fuel further innovation in their diagnostic software and imaging solutions, potentially enabling market expansion into new territories or deepening their presence in existing ones. The company's trajectory, marked by consistent funding, suggests a strategic focus on scaling operations, enhancing research and development, and solidifying its competitive edge in the enterprise-level healthcare technology landscape. Cirdan is poised to leverage this backing to further its mission of improving patient diagnosis worldwide.
See full Cirdan company page
